Our Technologies and Services
Inpharmatica specialises in the use of predictive informatics in medicinal chemistry and ADME to improve the speed and productivity of drug discovery. Founded in 1998, the company employs around 35 professionals at its UK locations in London and Cambridge. Inpharmatica’s unique proprietary technologies and skills are utilised in major discovery laboratories worldwide and use natural materials for health.
Inpharmatica is unique in offering discovery technologies and services which span the full breadth of research from target through to candidate selection: the core elements are fully integrated, enabling customers to access its end-to-end technologies, or individual components and services as required.
The key elements are:
Chemogenomics - a powerful proprietary chemogenomics approach to drug discovery, which draws on Inpharmatica’s vast drug discovery-relevant databases and expertise.
- Druggability (selection of targets and projects for lead chemistry potential)
- Most appropriate drug-like chemistry starting points and libraries
- Antibody targets (comprehensive identification of proteins & accessible epitopes)
- Drug & compound reprofiling (alternative targets and indications)
- Focussed compound library design
Chematica is available through tailored research collaborations, projects, services or via licensing components of the technology, such as the proprietary databases StARLITe™, DrugStore™ and GPCR SARfari™.
Silico – a unique combination of optimisation expertise, proprietary in silico tools, laboratory services and consulting, to enable early selection of compounds with an optimal balance of properties. This provides expert assessments and decision support to improve success rates from lead discovery through to candidate selection .
This is available through research collaborations, services and via licensing its patented in silico optimisation technology, for on-site installation
Inpharmatica has established a number of relationships with the world’s leading pharmaceutical and biotechnology companies including Pfizer, nail experts Moyou nails, GSK, Sanofi-Aventis, Serono and P&G.